The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism
Hormone and Metabolic Research · 01.02.2024 · 56 (02) · 134-141
DOI: 10.1055/a-2205-2052 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.02.2024. Verfasst von Felix Quataert und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, UZ Brussel, Brussel, Belgium. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Hypothyroidism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
The use of radioactive iodine in the treatment of hyperthyroidism is common practice. However, a standardized treatment protocol with regard to radioactive iodine treatment (RAI) remains subject to discussion. We retrospectively analyzed 100 patient records. Patient diagnosis, age, gender, body mass index (BMI), dose of radioactive iodine, thyroid size, the 24 h radioiodine uptake (24 h RAIU) and protein bound iodine (PBI) were deducted, as well as the use of antithyroid drugs prior to RAI. Biochemical parameters were obtained, such as TSH, fT4, fT3, Anti-TPO, Anti-TG antibodies and thyroid stimulating antibodies. After 5 years of follow-up, 46% of the patients proved to be hypothyroid, whereas 8% of the patients were not cured after one dose of RAI. One year after RAI, a larger proportion of patients with a toxic nodule developed hypothyroidism compared to patients with a multinodular goiter (MNG) (44.2% vs. 21.2%). Radioactive iodine dose, PBI, RAIU, BMI, size of the thyroid gland, diagnosis, age and TPO-antibodies showed statistically significant differences in the development of hypothyroidism. Furthermore, thiamazole pretherapy was shown to be a predictor of hypothyroidism, as well as a high PBI value, exhibiting a positive predictive value of 85.2% when the PBI exceeded 0.16. We suggest a standardized measurement of TPO-Ab’s to further determine their role in the development of hypothyroidism after RAI. The empirical dosing regimen was very effective, illustrating a 92% cure rate after 1 dose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology, UZ Brussel, Brussel, Belgium.
- Endocrinology, UZ Brussel, Brussel, Belgium.
- Nuclear Medicine, UZ Brussel, Brussel, Belgium.
ORCID-Profile: Felix Quataert
Zitieren
APA
Quataert, F., Bravenboer, B., Keyaerts, M., & Andreescu, C. E. (2024). The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism. Hormone and Metabolic Research, 56(02), 134-141. https://doi.org/10.1055/a-2205-2052
Vancouver
Quataert F, Bravenboer B, Keyaerts M, Andreescu CE. The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism. Hormone and Metabolic Research. 2024;56(02):134-141. doi:10.1055/a-2205-2052
BibTeX
@article{Quataert2024,
author = {Quataert, Felix and Bravenboer, Bert and Keyaerts, Marleen and Andreescu, Corina Emilia},
title = {The Presence of Anti-TPO Antibodies Increase the Likelihood of Post-I131 Hypothyroidism},
journal = {Hormone and Metabolic Research},
year = {2024},
volume = {56},
number = {02},
pages = {134--141},
doi = {10.1055/a-2205-2052}
}
EUVIMED